PKU treatment, Palynziq, receives FDA approval

The U.S. Food and Drug Administration today approved Palynziq (pegvaliase-pqpz) for adults with arare and serious genetic disease known as phenylketonuria (PKU). Patients with PKU are born with an inability to break down phenylalanine (Phe), an amino acid present in protein-containing foods and high-intensity sweeteners used in a variety of foods and beverages. Palynziq is a novel enzyme therapy for ["]

The post PKU treatment, Palynziq, receives FDA approval appeared first on Outbreak News Today.